REGULATORY

• MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
  February 25, 2021

• 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
  February 24, 2021

• MHLW Not Discussing Single-Dose Use of COVID-19 Vaccine: Minister
  February 24, 2021

• Incyte’s Pemigatinib Clears PAFSC, March Approval Likely
  February 24, 2021

• LDP COVID-19 Project Team to Compile Proposal on Single Vaccine Dose
  February 24, 2021

• Orphan Status Granted to Novo’s Concizumab, Eisai’s E7090 and More
  February 24, 2021

• LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
  February 22, 2021

• Whether to Get COVID-19 Vaccines Up to Individuals to Decide: Govt
  February 22, 2021

• First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
  February 22, 2021

• Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
  February 22, 2021

• Govt Plans Ticket Barcode Scan for New Vaccination Tracking System
  February 18, 2021

• Japan Might Reconsider Vaccine Use for Kids under Age 16 If Data Obtained
  February 18, 2021

• Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
  February 18, 2021

• Japan Launches COVID-19 Vaccination Program
  February 18, 2021

• MHLW Hints It Might Take 1 Year for Kobayashi Kako to Resume Operations
  February 17, 2021

• COVID-19 Vaccine Being Rolled Out for 40,000 Healthcare Workers in Japan
  February 17, 2021

• Pregnant Women Not Urged to “Make Efforts” to Get COVID-19 Vaccines
  February 16, 2021

• Chugai’s Blood-Based Genomic Profiling Test Now in Line for March OK
  February 16, 2021

• PAFSC Minutes for Pfizer Vaccine Review Due Out around Feb. 26
  February 16, 2021

• 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
  February 16, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 162
• 163
• 164
• 165
• 166
• 167
• 168
• 169
• 170
• …
• Next ›
• 最終 »